Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 93

1.

HIV-1 envelope subregion length variation during disease progression.

Curlin ME, Zioni R, Hawes SE, Liu Y, Deng W, Gottlieb GS, Zhu T, Mullins JI.

PLoS Pathog. 2010 Dec 16;6(12):e1001228. doi: 10.1371/journal.ppat.1001228.

4.

N-linked glycosylation of the HIV type-1 gp120 envelope glycoprotein as a major determinant of CCR5 and CXCR4 coreceptor utilization.

Pollakis G, Kang S, Kliphuis A, Chalaby MI, Goudsmit J, Paxton WA.

J Biol Chem. 2001 Apr 20;276(16):13433-41. Epub 2001 Jan 16.

5.

Longer V1V2 region with increased number of potential N-linked glycosylation sites in the HIV-1 envelope glycoprotein protects against HIV-specific neutralizing antibodies.

van Gils MJ, Bunnik EM, Boeser-Nunnink BD, Burger JA, Terlouw-Klein M, Verwer N, Schuitemaker H.

J Virol. 2011 Jul;85(14):6986-95. doi: 10.1128/JVI.00268-11. Epub 2011 May 18.

6.
7.

Temporal relationship between V1V2 variation, macrophage replication, and coreceptor adaptation during HIV-1 disease progression.

Masciotra S, Owen SM, Rudolph D, Yang C, Wang B, Saksena N, Spira T, Dhawan S, Lal RB.

AIDS. 2002 Sep 27;16(14):1887-98.

PMID:
12351948
8.

Association between gp120 envelope V1V2 and V4V5 variable loop profiles in a defined HIV-1 transmission cluster.

Pollakis G, Baan E, van Werkhoven MB, Berkhout B, Bakker M, Jurriaans S, Paxton WA.

AIDS. 2015 Jun 19;29(10):1161-71. doi: 10.1097/QAD.0000000000000692.

PMID:
26035318
9.

The role of the humoral immune response in the molecular evolution of the envelope C2, V3 and C3 regions in chronically HIV-2 infected patients.

Borrego P, Marcelino JM, Rocha C, Doroana M, Antunes F, Maltez F, Gomes P, Novo C, Barroso H, Taveira N.

Retrovirology. 2008 Sep 8;5:78. doi: 10.1186/1742-4690-5-78.

10.

The V1V2 Region of HIV-1 gp120 Forms a Five-Stranded Beta Barrel.

Pan R, Gorny MK, Zolla-Pazner S, Kong XP.

J Virol. 2015 Aug;89(15):8003-10. doi: 10.1128/JVI.00754-15. Epub 2015 May 27.

11.

The V1V2 domain and an N-linked glycosylation site in the V3 loop of the HIV-1 envelope glycoprotein modulate neutralization sensitivity to the human broadly neutralizing antibody 2G12.

Chaillon A, Braibant M, Moreau T, Thenin S, Moreau A, Autran B, Barin F.

J Virol. 2011 Apr;85(7):3642-8. doi: 10.1128/JVI.02424-10. Epub 2011 Jan 19.

12.

V3 loop truncations in HIV-1 envelope impart resistance to coreceptor inhibitors and enhanced sensitivity to neutralizing antibodies.

Laakso MM, Lee FH, Haggarty B, Agrawal C, Nolan KM, Biscone M, Romano J, Jordan AP, Leslie GJ, Meissner EG, Su L, Hoxie JA, Doms RW.

PLoS Pathog. 2007 Aug 24;3(8):e117.

13.

Genetic diversity of the highly variable V1 region interferes with Human Immunodeficiency Virus type 1 envelope functionality.

Hamoudi M, Simon-Loriere E, Gasser R, Negroni M.

Retrovirology. 2013 Oct 24;10:114. doi: 10.1186/1742-4690-10-114.

14.
15.

Escape from autologous neutralizing antibodies in acute/early subtype C HIV-1 infection requires multiple pathways.

Rong R, Li B, Lynch RM, Haaland RE, Murphy MK, Mulenga J, Allen SA, Pinter A, Shaw GM, Hunter E, Robinson JE, Gnanakaran S, Derdeyn CA.

PLoS Pathog. 2009 Sep;5(9):e1000594. doi: 10.1371/journal.ppat.1000594. Epub 2009 Sep 18.

16.

Levels of N-linked glycosylation on the V1 loop of HIV-1 Env proteins and their relationship to the antigenicity of Env from primary viral isolates.

Huang Z, Chou A, Tanguay J, Shen S, Mboudjeka I, Chou TH, Lu S, Wang S.

Curr HIV Res. 2008 Jun;6(4):296-305.

PMID:
18691028
17.

Role of V1V2 and other human immunodeficiency virus type 1 envelope domains in resistance to autologous neutralization during clade C infection.

Rong R, Bibollet-Ruche F, Mulenga J, Allen S, Blackwell JL, Derdeyn CA.

J Virol. 2007 Feb;81(3):1350-9. Epub 2006 Nov 1. Erratum in: J Virol. 2007 Nov;81(22):12715.

18.

Molecular evolution of HIV-1 CRF01_AE Env in Thai patients.

Boonchawalit S, Jullaksorn D, Uttiyoung J, Yowang A, Krathong N, Chautrakul S, Yamashita A, Ikuta K, Roobsoong A, Kanitvittaya S, Sawanpanyalert P, Kameoka M.

PLoS One. 2011;6(11):e27098. doi: 10.1371/journal.pone.0027098. Epub 2011 Nov 2.

19.

Evolution of human immunodeficiency virus type 2 coreceptor usage, autologous neutralization, envelope sequence and glycosylation.

Shi Y, Brandin E, Vincic E, Jansson M, Blaxhult A, Gyllensten K, Moberg L, Broström C, Fenyö EM, Albert J.

J Gen Virol. 2005 Dec;86(Pt 12):3385-96.

PMID:
16298986
20.

Partial rescue of V1V2 mutant infectivity by HIV-1 cell-cell transmission supports the domain's exceptional capacity for sequence variation.

Brandenberg OF, Rusert P, Magnus C, Weber J, Böni J, Günthard HF, Regoes RR, Trkola A.

Retrovirology. 2014 Sep 25;11:75. doi: 10.1186/s12977-014-0075-y.

Items per page

Supplemental Content

Write to the Help Desk